SCHEMBL335876

SCHEMBL335876

CN1CCN(c2nc3c(N4CCOCC4)nc(-c4cnc(NC(=O)O)nc4)nc3n2CC(F)(F)F)CC1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 14/20 0.46
MTOR P42345 8/20 0.46
PIK3CD O00329 6/20 0.46
PIK3CG P48736 3/20 0.46
HDAC1 Q13547 7/20 0.43
PIK3R1 P27986 4/20 0.43
PIK3CB P42338 2/20 0.42
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
HDAC9 Q9UKV0 1/20 0.42
HDAC5 Q9UQL6 1/20 0.42
NCOR2 Q9Y618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL336300 0.92 PIK3CA (0.47) PIK3CAMTORPIK3CDPIK3CGHDAC1
SCHEMBL363794 0.91 PIK3CA (0.46) PIK3CAMTORPIK3CDPIK3CGHDAC1
SCHEMBL775310 0.91 PIK3CA (0.44) PIK3CAMTORPIK3CDPIK3CGHDAC1
SCHEMBL336630 0.90 PIK3CA (0.44) PIK3CAMTORPIK3CDPIK3CGHDAC1
SCHEMBL799180 0.90 MTOR (0.49) PIK3CAMTORPIK3CDPIK3CGHDAC1
SCHEMBL336980 0.89 HDAC1 (0.43) PIK3CAMTORPIK3CDPIK3CGHDAC1
SCHEMBL799267 0.89 PIK3CA (0.47) PIK3CAMTORPIK3CDPIK3CGHDAC1
SCHEMBL336275 0.86 PIK3CA (0.59) PIK3CAMTORPIK3CDPIK3CGHDAC1
SCHEMBL2843039 0.86 PIK3CA (0.47) PIK3CAMTORPIK3CDPIK3CGHDAC1
SCHEMBL337051 0.84 PIK3CA (0.44) PIK3CAMTORPIK3CDPIK3CGHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2336132-B1 MORPHOLINOPURINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2014-01-01 EP disclosed
US-8309546-B2 Morpholinopurine derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-11-13 US disclosed
US-20120071476-A1 MORPHOLINOPURINE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-22 US disclosed
US-8097622-B2 Morpholinopurine derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-17 US disclosed
EP-2336132-A1 MORPHOLINOPURINE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2011-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071476-A1 MORPHOLINOPURINE DERIVATIVES MTOR, RICTOR, PIK3R1 PIK3CA 22/4885MTOR 1/4885PIK3CD 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.